You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

  • Product nameAnti-Met (c-Met) antibody [8F11]See all Met (c-Met) primary antibodies ...
  • Description
    Mouse monoclonal [8F11] to Met (c-Met)
  • Tested applicationsIHC-Fr, IHC-P more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Prokaryotic recombinant protein corresponding to the external domain of the beta chain of the cMET molecule.

  • Positive controlHuman Prostate epithelium.

Properties

Applications

Our Abpromise guarantee covers the use of ab49210 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-Fr IHC-Fr: 1/20 - 1/30.
IHC-P IHC-P: 1/20 - 1/30. Perform heat mediated antigen retrieval before commencing with IHC staining protocol. Incubate with primary antibody for 60 minutes at 25°C using standard ABC method.
  • Application notesIs unsuitable for or WB.

    • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.

      • Target information above from: UniProt accession P08581 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt
    • Database links
      • Alternative names
          AUTS9 antibodyc met antibodycmet antibody
          D249 antibodyHepatocyte growth factor receptor antibodyHepatocyte growth factor receptor Precursor antibodyHGF antibodyHGF receptor antibodyHGF SF receptor antibodyHGF/SF receptor antibodyHGFR antibodyMET antibodyMet proto oncogene tyrosine kinase antibodyMet proto-oncogene (hepatocyte growth factor receptor) antibodyMet proto-oncogene antibodyMet protooncogene antibodyMET_HUMAN antibodyOncogene MET antibodyPar4 antibodyProto-oncogene c-Met antibodyRCCP2 antibodyRenal cell carcinoma papillary 2 gene antibodyScatter factor receptor antibodySF receptor antibodyTyrosine-protein kinase Met antibody
        see all

      References for Anti-Met (c-Met) antibody [8F11] (ab49210)

      This product has been referenced in:
      • Stein U  et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15:59-67 (2009). IHC-P ; Human . Read more (PubMed: 19098908) »
      • Montag M  et al. Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. Cancer Sci 100:1210-8 (2009). Read more (PubMed: 19385965) »

      See all 2 Publications for this product

      Publishing research using ab49210 ? Please let us know so that we can cite the reference in this datasheet

      Product Wall

      Submit an Abreview for ab49210 Submit a Question for ab49210

      Displaying 1 - 1 of 1 results for Abreviews and Q&A

      10
      Votes: Highest First

      Are any references available regarding generation of this antibody or further characterization of the antibody?

      With regard to the antibody NCL-cmet, a full assessment of the antibody was published in Claire Chapman's thesis (Newcastle University). This can be accessed via Pub Med Central the thesis title is:- Role of c-met in response to liver injury and in c...

      Read More

      Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"